Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma
PR Newswire - Wed Apr 09, 7:47AM CDT
On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 08, 12:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Apr 04, 7:50AM CDT
These under-$10 stocks are within range of triggering breakout trades.
North East Dental Management Welcomes Steven W. Jones As Chief Corporate Development & Integration Officer
PR Newswire - Wed Apr 02, 2:00PM CDT
North East Dental Management (NEDM), a dental services organization, is pleased to announce the appointment of Steven W. Jones, DPh, MBA as its Chief Corporate Development & Integration Officer. Steven brings almost 30 years of experience in healthcare management, spanning successful clinical, leadership, and corporate development positions within a variety of healthcare segments. His responsibilities as Chief Corporate Development & Integration Officer for NEDM include sourcing acquisitions and affiliations, negotiating deals, running the due diligence process, and overseeing the post-acquisition integration into the company.
BioScrip Completes Sale of Home Health Services Business to LHC Group
PR Newswire - Tue Apr 01, 6:06AM CDT
BioScrip®, Inc. (NASDAQ: BIOS) today announced that it has completed the previously announced sale of substantially all of its Home Health business, known as Deaconess HomeCare, to LHC Group, Inc. (NASDAQ: LHCG). The transaction represents a total deal value of approximately $60 million. BioScrip intends to use the net proceeds from the sale to pay down a portion of its outstanding debt.
LHC Group Completes Acquisition of Deaconess HomeCare
GlobeNewswire - Tue Apr 01, 6:03AM CDT
LHC Group Inc. (Nasdaq:LHCG), a national provider of home health, hospice and comprehensive post-acute healthcare services, announced today that it has completed the previously announced transaction with BioScrip(R), Inc. (Nasdaq:BIOS) to purchase two of its operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $59.5 million. The transaction adds 32 agencies in four states, increasing LHC Group's geographical footprint to 340 post-acute care agencies across 26 states, and is anticipated to be accretive to LHC Group's 2014 earnings by between $0.05 and $0.10 per diluted share.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
BioScrip Now in Strong Sell Territory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 3:05PM CST
On Mar 4, 2014, Zacks Investment Research downgraded BioScrip to a Zacks Rank #5 (Strong Sell).
Weakness Seen in BioScrip (BIOS) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:36AM CST
BioScrip has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
BioScrip (BIOS) in Focus: Stock Tanks 12.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:47AM CST
BioScrip stock dropped 12.3% yesterday, falling below its one month volatile price range of $7.96 to $8.69
Downgrade Alert for BioScrip (BIOS)
Comtex SmarTrend(R) - Fri Feb 28, 7:03AM CST
BioScrip (NASDAQ:BIOS) was downgraded from Buy to Neutral at Sidoti today. The stock closed yesterday at $7.40 on volume of 8.2 million shares, above average daily volume of 1.5 million. BioScrip, Inc. is a pharmacy benefit management and specialty pharmaceutical organization that partners with managed care organizations and healthcare providers to control prescription drug costs. The Company provides pharmacy benefit products and services and mail order pharmacy services, and is the fulfillment center for online retailers offering prescription and OTC products.
Why BioScrip Inc. Shares Stumbled
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 27, 2:29PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BioScrip , a provider of home care...
BioScrip Reports Fourth Quarter 2013 Financial Results
PR Newswire - Wed Feb 26, 4:03PM CST
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 fourth quarter financial results. Fourth quarter revenue from continuing operations was $243.5 million and the net loss from continuing operations was $15.4 million, or $0.23 per basic and diluted share.